Tenosynovial Giant Cell Tumors Pipeline Insights and Analysis 2024: FDA Approvals, Therapies, MOA, ROA, and Developments | Deciphera Pharma, Elixiron Immunotherapeutics, Daiichi Sankyo, Abbisko Thera

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tenosynovial Giant Cell Tumors pipeline constitutes 5+ key companies continuously working towards developing 5+ Tenosynovial Giant Cell Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Tenosynovial Giant Cell Tumors Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tenosynovial Giant Cell Tumors Market.

The Tenosynovial Giant Cell Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Tenosynovial Giant Cell Tumors Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Tenosynovial Giant Cell Tumors treatment therapies with a considerable amount of success over the years.

*
Tenosynovial Giant Cell Tumors companies working in the treatment market are Deciphera Pharmaceuticals, Elixiron Immunotherapeutics, Daiichi Sankyo Co., Ltd., Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others, are developing therapies for the Tenosynovial Giant Cell Tumors treatment

*
Emerging Tenosynovial Giant Cell Tumors therapies in the different phases of clinical trials are- Vimseltinib, EI-1071, Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others are expected to have a significant impact on the Tenosynovial Giant Cell Tumors market in the coming years.

*
In August 2024, Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President: Toichi Takino) announced that the U.S. Food and Drug Administration (FDA) has accepted a priority review for vimseltinib, a colony stimulating factor 1 receptor (CSF1R) inhibitor, for treating patients with tenosynovial giant cell tumor (TGCT). The New Drug Application (NDA) was submitted on August 14, 2023, and Deciphera Pharmaceuticals, a wholly-owned subsidiary of Ono, is developing the drug. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of February 17, 2025. In mid-July, the European Medicines Agency (EMA) also accepted vimseltinib's Marketing Authorization Application (MAA), beginning the centralized review process.

*
In July 2024, The European Medicines Agency (EMA) has accepted Deciphera Pharmaceuticals, a subsidiary of Ono Pharmaceutical, for the review of their marketing authorization application (MAA) for vimseltinib, aimed at treating tenosynovial giant cell tumor (TGCT). Vimseltinib is a colony-stimulating factor 1 receptor (CSF1R) inhibitor.

Tenosynovial Giant Cell Tumors Overview

Tenosynovial Giant Cell Tumors (TGCT) are rare, benign tumors that occur in the synovial lining of joints, tendons, or bursae. These tumors can be locally aggressive, leading to pain, swelling, and reduced mobility in the affected area, often impacting the knee, hip, or hand. TGCT is divided into two types: localized (often found in tendons) and diffuse (which can involve entire joints). While typically non-cancerous, they can cause significant joint damage if left untreated. Treatment options include surgery, radiation, and emerging targeted therapies like CSF1R inhibitors.

Get a Free Sample PDF Report to know more about Tenosynovial Giant Cell Tumors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight [https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Tenosynovial Giant Cell Tumors Drugs Under Different Phases of Clinical Development Include:

*
Vimseltinib: Deciphera Pharmaceuticals

*
EI-1071: Elixiron Immunotherapeutics

*
Pexidartinib: Daiichi Sankyo Co., Ltd.

*
vimseltinib: Deciphera Pharmaceuticals

*
Pimicotinib(ABSK021): Abbisko Therapeutics

*
AMB-05X: AmMax Bio, Inc.

*
Emactuzumab: SynOx Therapeutics Limited

*
Pimicotinib(ABSK021): Abbisko Therapeutics

*
FPA008: Five Prime Therapeutics

*
MCS110: Novartis

Tenosynovial Giant Cell Tumors Route of Administration

Tenosynovial Giant Cell Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Tenosynovial Giant Cell Tumors Molecule Type

Tenosynovial Giant Cell Tumors Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Tenosynovial Giant Cell Tumors Pipeline Therapeutics Assessment

*
Tenosynovial Giant Cell Tumors Assessment by Product Type

*
Tenosynovial Giant Cell Tumors By Stage and Product Type

*
Tenosynovial Giant Cell Tumors Assessment by Route of Administration

*
Tenosynovial Giant Cell Tumors By Stage and Route of Administration

*
Tenosynovial Giant Cell Tumors Assessment by Molecule Type

*
Tenosynovial Giant Cell Tumors by Stage and Molecule Type

DelveInsight's Tenosynovial Giant Cell Tumors Report covers around 5+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Tenosynovial Giant Cell Tumors product details are provided in the report. Download the Tenosynovial Giant Cell Tumors pipeline report to learn more about the emerging Tenosynovial Giant Cell Tumors therapies [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Tenosynovial Giant Cell Tumors Therapeutics Market include:

Key companies developing therapies for Tenosynovial Giant Cell Tumors are - Elixiron Immunotherapeutics, AmMax Bio, Inc., Deciphera Pharmaceuticals, Novartis Oncology, and others.

Tenosynovial Giant Cell Tumors Pipeline Analysis:

The Tenosynovial Giant Cell Tumors pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Tenosynovial Giant Cell Tumors with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tenosynovial Giant Cell Tumors Treatment.

*
Tenosynovial Giant Cell Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Tenosynovial Giant Cell Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tenosynovial Giant Cell Tumors market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Tenosynovial Giant Cell Tumors drugs and therapies [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Tenosynovial Giant Cell Tumors Pipeline Market Drivers

*
Increasing Prevalence, Advances in Targeted Therapies, Ongoing Clinical Trials, Growing Investment in Research, Rising Awareness, are some of the important factors that are fueling the Tenosynovial Giant Cell Tumors Market.

Tenosynovial Giant Cell Tumors Pipeline Market Barriers

*
However, High Treatment Costs, Limited Approved Therapies, Adverse Side Effects, Delayed Diagnosis, and other factors are creating obstacles in the Tenosynovial Giant Cell Tumors Market growth.

Scope of Tenosynovial Giant Cell Tumors Pipeline Drug Insight

*
Coverage: Global

*
Key Tenosynovial Giant Cell Tumors Companies: Deciphera Pharmaceuticals, Elixiron Immunotherapeutics, Daiichi Sankyo Co., Ltd., Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others

*
Key Tenosynovial Giant Cell Tumors Therapies: Vimseltinib, EI-1071, Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others

*
Tenosynovial Giant Cell Tumors Therapeutic Assessment: Tenosynovial Giant Cell Tumors current marketed and Tenosynovial Giant Cell Tumors emerging therapies

*
Tenosynovial Giant Cell Tumors Market Dynamics: Tenosynovial Giant Cell Tumors market drivers and Tenosynovial Giant Cell Tumors market barriers

Request for Sample PDF Report for Tenosynovial Giant Cell Tumors Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Tenosynovial Giant Cell Tumors Report Introduction

2. Tenosynovial Giant Cell Tumors Executive Summary

3. Tenosynovial Giant Cell Tumors Overview

4. Tenosynovial Giant Cell Tumors- Analytical Perspective In-depth Commercial Assessment

5. Tenosynovial Giant Cell Tumors Pipeline Therapeutics

6. Tenosynovial Giant Cell Tumors Late Stage Products (Phase II/III)

7. Tenosynovial Giant Cell Tumors Mid Stage Products (Phase II)

8. Tenosynovial Giant Cell Tumors Early Stage Products (Phase I)

9. Tenosynovial Giant Cell Tumors Preclinical Stage Products

10. Tenosynovial Giant Cell Tumors Therapeutics Assessment

11. Tenosynovial Giant Cell Tumors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Tenosynovial Giant Cell Tumors Key Companies

14. Tenosynovial Giant Cell Tumors Key Products

15. Tenosynovial Giant Cell Tumors Unmet Needs

16 . Tenosynovial Giant Cell Tumors Market Drivers and Barriers

17. Tenosynovial Giant Cell Tumors Future Perspectives and Conclusion

18. Tenosynovial Giant Cell Tumors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tenosynovial-giant-cell-tumors-pipeline-insights-and-analysis-2024-fda-approvals-therapies-moa-roa-and-developments-deciphera-pharma-elixiron-immunotherapeutics-daiichi-sankyo-abbisko-thera]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.